Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
7
×
biotech
eli lilly
7
×
life sciences
national
national blog main
national top stories
new york blog main
7
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
fda
merck
startups
alzheimer's disease
astrazeneca
bristol-myers squibb
pfizer
allergan
amgen
What
bio
roundup
drug
companies
fda
news
week
approved
biotech
debut
moves
nash
new
treatment
acquisitions
adults
allergan
alzheimer’s
annual
approval
assessed
attention
august
biggest
biogen’s
biopharmaceutical
black
build
busy
buy
ceo
class
communities
company’s
conference
continue
convo
daniel
days
decisions
Language
unset
Current search:
abbvie
×
" new york blog main "
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More